Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2318]

Chemoimmunotherapy or BTK inhibition for patients with CLL

Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany

Chemoimmunotherapy or BTK inhibition for patients with CLL ( Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany )

The changing landscape of AML

Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany

The changing landscape of AML ( Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany )

CLL14: A chemotherapy-free regimen of venetoclax plus obinutuzumab for CLL

Dr Othman Al-Sawaf - Univesity of Cologne, Cologne, Germany

CLL14: A chemotherapy-free regimen of venetoclax plus obinutuzumab for CLL ( Dr Othman Al-Sawaf - Univesity of Cologne, Cologne, Germany )

CD33 T cell recruiting antibody constructs for treatment of relapsed refractory...

Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany

$CD33 T cell recruiting antibody constructs for treatment of relapsed refractory AML ( Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany )$

Targeted treatment of AML using T cell recruiting antibody constructs

Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany

Targeted treatment of AML using T cell recruiting antibody constructs ( Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany )

PARP inhibitors olaparib and talazoparib as treatment for metastatic breast...

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

PARP inhibitors olaparib and talazoparib as treatment for metastatic breast cancer ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Are PARP inhibitors a new standard of care option for MBC patients?

Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston...

Are PARP inhibitors a new standard of care option for MBC patients? ( Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston, USA )

The potential of PARP inhibitors in new cancer groups and in combination with...

Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston...

The potential of PARP inhibitors in new cancer groups and in combination with other treatments ( Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston, USA )

Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions

Dr Joel Neal - Stanford University, Stanford, USA

Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions ( Dr Joel Neal - Stanford University, Stanford, USA )

Cutting-edge cancer care at the Miami Cancer Institute

Dr Miguel Villalona - Miami Cancer Institute, Miami, USA

Cutting-edge cancer care at the Miami Cancer Institute ( Dr Miguel Villalona - Miami Cancer Institute, Miami, USA )

Comment: Pregnancy outcomes in patients with chronic myeloid leukaemia

Prof Anton Hagenbeek - University of Amsterdam, Amsterdam, The Netherlands

Comment: Pregnancy outcomes in patients with chronic myeloid leukaemia ( Prof Anton Hagenbeek - University of Amsterdam, Amsterdam, The Netherlands )

Comment: Fixed-duration venetoclax plus obinutuzumab in patients with CLL and...

Prof Anton Hagenbeek - University of Amsterdam, Amsterdam, The Netherlands

Comment: Fixed-duration venetoclax plus obinutuzumab in patients with CLL and comorbidities ( Prof Anton Hagenbeek - University of Amsterdam, Amsterdam, The Netherlands )

More from ecancer